Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Episode Clear all
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Practical Application of Accelerated iTBS for MDD

NCT06113575
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
Interventions
NeuroStar TMS
Device
Lead sponsor
Sonder Behavioral Health and Wellness
Other
Eligibility
22 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

NCT00094432
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
40
States / cities
Mesa, Arizona • La Mesa, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 17, 2026, 6:19 AM EDT
Not listed Phase 2 Interventional

A Single Ketamine Infusion Combined With Music for Suicidal Ideation

NCT04658420
View directory record Official record
Conditions
Suicidal Ideation, Depressive Episode
Interventions
Ketamine Hydrochloride, Music
Drug · Other
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 17, 2026, 6:19 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

NCT07621237
View directory record Official record
Conditions
Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Interventions
TNX-102 SL, Placebo sublingual tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Chino, California • Lemon Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

NCT00237666
View directory record Official record
Conditions
Bipolar II Disorder, Major Depressive Episode
Interventions
Ziprasidone
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
New York, New York • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 17, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS

NCT04870255
View directory record Official record
Conditions
Depressive Disorder, Major, Borderline Personality Disorder
Interventions
Left Dorsolateral Prefrontal Cortex (L-DLPFC), Dorsomedial Prefrontal Cortex (DMPFC), Sham Stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 17, 2026, 6:19 AM EDT
Terminated Phase 4 Interventional

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

NCT03537547
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode, Depression, Unipolar
Interventions
GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment
Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Suicidality in Bipolar Depression

NCT01944293
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

NCT01684163
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole in Patients With Major Depressive Disorder

NCT00105196
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole+ ADT, Placebo+ ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

NCT00825019
View directory record Official record
Conditions
Major Depressive Disorders
Interventions
amibegron (SR58611A), placebo, paroxetine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 17, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

NCT05169710
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 4 Interventional

Effectiveness of Pramipexole for Treatment-Resistant Depression

NCT00231959
View directory record Official record
Conditions
Depression
Interventions
Pramipexole (Mirapex), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Sep 17, 2026, 6:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

NCT03336918
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Depression, Bipolar II Depression, Bipolar Depression, Depression, Major Depressive Episode
Interventions
Lithium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional

Augmented Depression Therapy (ADepT) Case Series

NCT07733310
View directory record Official record
Conditions
Depression / Major Depressive Disorder
Interventions
Augmented Depression Therapy (ADepT)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treating Depression With Transcranial Direct Current Stimulation (tDCS)

NCT00481988
View directory record Official record
Conditions
Depression
Interventions
transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 17, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

NCT06523439
View directory record Official record
Conditions
Major Depressive Disorder, Depression in Adolescence, Depression, Major Depressive Episode
Interventions
MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
13 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression

NCT03349528
View directory record Official record
Conditions
Bipolar Depression
Interventions
Probiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional

BHV-7000 Open-Label Extension Bipolar Mania Study

NCT06423794
View directory record Official record
Conditions
Bipolar Disorder
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2Phase 3 Interventional

BHV-7000 Acute Treatment of Bipolar Mania

NCT06419582
View directory record Official record
Conditions
Bipolar Disorder
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

NCT00672620
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 17, 2026, 6:19 AM EDT